Structural Genomics Consortium, University of Oxford, Headington, UK.
Botnar Research Centre, NIHR Oxford Biomedical Research Unit, University of Oxford, Oxford, UK.
Nat Chem Biol. 2016 Jul;12(7):539-45. doi: 10.1038/nchembio.2087. Epub 2016 May 23.
Members of the KDM5 (also known as JARID1) family are 2-oxoglutarate- and Fe(2+)-dependent oxygenases that act as histone H3K4 demethylases, thereby regulating cell proliferation and stem cell self-renewal and differentiation. Here we report crystal structures of the catalytic core of the human KDM5B enzyme in complex with three inhibitor chemotypes. These scaffolds exploit several aspects of the KDM5 active site, and their selectivity profiles reflect their hybrid features with respect to the KDM4 and KDM6 families. Whereas GSK-J1, a previously identified KDM6 inhibitor, showed about sevenfold less inhibitory activity toward KDM5B than toward KDM6 proteins, KDM5-C49 displayed 25-100-fold selectivity between KDM5B and KDM6B. The cell-permeable derivative KDM5-C70 had an antiproliferative effect in myeloma cells, leading to genome-wide elevation of H3K4me3 levels. The selective inhibitor GSK467 exploited unique binding modes, but it lacked cellular potency in the myeloma system. Taken together, these structural leads deliver multiple starting points for further rational and selective inhibitor design.
KDM5(也称为 JARID1)家族的成员是依赖 2-氧戊二酸和 Fe(2+)的氧合酶,作为组蛋白 H3K4 去甲基酶,从而调节细胞增殖和干细胞自我更新和分化。在这里,我们报告了人 KDM5B 酶催化核心与三种抑制剂化学型复合物的晶体结构。这些支架利用了 KDM5 活性位点的几个方面,其选择性谱反映了它们相对于 KDM4 和 KDM6 家族的混合特征。先前鉴定的 KDM6 抑制剂 GSK-J1 对 KDM5B 的抑制活性比 KDM6 蛋白低约七倍,而 KDM5-C49 对 KDM5B 和 KDM6B 的选择性为 25-100 倍。具有细胞渗透性的衍生物 KDM5-C70 在骨髓瘤细胞中具有抗增殖作用,导致 H3K4me3 水平在全基因组范围内升高。选择性抑制剂 GSK467 利用了独特的结合模式,但在骨髓瘤系统中缺乏细胞效力。总之,这些结构线索为进一步的合理和选择性抑制剂设计提供了多个起点。